High Smad7 in the Early Post-operative Recurrence of Crohn's Disease

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2020 Oct 20

PMID 33076905

Citations 6

Authors

Francesca Zorzi

Emma Calabrese

Davide Di Fusco

Elena De Cristofaro

Livia Biancone

Sara Casella

Giampiero Palmieri

Giovanni Monteleone

Affiliations

Soon will be listed here.

Abstract

Background: In Crohn's disease (CD), one of the major inflammatory bowel disease (IBD) in human beings, there is over-expression of Smad7, an intracellular inhibitor of the suppressive cytokine TGF-β1. The aim of this study was to assess whether Smad7 over-expression occurs in the early and/or late phases of CD.

Methods: Mucosal samples were taken from the neo-terminal ileum of CD patients undergoing ileocolonic resection, with or without (early CD) post-operative endoscopic recurrence, and terminal ileum of CD patients with long-standing disease undergoing intestinal resection (late CD). Smad7 was examined by immunohistochemistry and cytokine expression was analysed by flow-cytometry.

Results: Before the appearance of endoscopic lesions, the mucosa of the neo-terminal ileum contained high number of Smad7-expressing cells in both the epithelial and lamina propria compartments. Transition from this stage to endoscopic recurrence was marked by persistence of high number of Smad7-positive cells, which reduced significantly in the late stages of the disease, where Smad7 expression remained, however, greater than that seen in normal controls. In samples with early lesions, Smad7 expression positively correlated with the number of interferon-γ-secreting cells.

Conclusions: Smad7 induction is an early event in the inflammatory sequence occurring in CD, thus suggesting that knockdown of Smad7 can help prevent post-operative recurrence.

Citing Articles

Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota.

Li J, Ji Y, Chen N, Dai L, Deng H Cell Biosci. 2023; 13(1):194.

PMID: 37875976 PMC: 10594787. DOI: 10.1186/s13578-023-01139-8.

Smad7 as a positive regulator of intestinal inflammatory diseases.

Monteleone G, Laudisi F, Stolfi C Curr Res Immunol. 2023; 4:100055.

PMID: 36714553 PMC: 9881044. DOI: 10.1016/j.crimmu.2023.100055.

Regulatory T cells as a therapeutic approach for inflammatory bowel disease.

Laukova M, Glatman Zaretsky A Eur J Immunol. 2022; 53(2):e2250007.

PMID: 36562391 PMC: 10107179. DOI: 10.1002/eji.202250007.

Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis.

Bai B, Li H, Han L, Mei Y, Hu C, Mei Q Mol Med Rep. 2022; 25(4).

PMID: 35137923 PMC: 8855156. DOI: 10.3892/mmr.2022.12632.

Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System.

Yau Y, Wasinger V, Hirten R, Chuang E, Huntsman M, Stylli J Inflamm Bowel Dis. 2021; 27(Suppl 2):S17-S24.

PMID: 34791290 PMC: 9214562. DOI: 10.1093/ibd/izab179.

References

Eftychi C, Schwarzer R, Vlantis K, Wachsmuth L, Basic M, Wagle P . Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity. 2019; 51(2):367-380.e4. DOI: 10.1016/j.immuni.2019.06.008. View

Strober W, Fuss I, Mannon P . The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117(3):514-21. PMC: 1804356. DOI: 10.1172/JCI30587. View

Fuss I, Neurath M, Boirivant M, Klein J, de La Motte C, Strong S . Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157(3):1261-70. View

Monteleone G, Pallone F, Macdonald T . Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol. 2004; 25(10):513-7. DOI: 10.1016/j.it.2004.07.008. View

Rutgeerts P, Geboes K, VANTRAPPEN G, KERREMANS R, Coenegrachts J, Coremans G . Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984; 25(6):665-72. PMC: 1432363. DOI: 10.1136/gut.25.6.665. View

Sachar D, Wolfson D, Greenstein A, Goldberg J, Styczynski R, Janowitz H . Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology. 1983; 85(4):917-21. View

Monteleone G, Boirivant M, Pallone F, MacDonald T . TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol. 2008; 1 Suppl 1:S50-3. DOI: 10.1038/mi.2008.55. View

Kaser A, Zeissig S, Blumberg R . Inflammatory bowel disease. Annu Rev Immunol. 2010; 28:573-621. PMC: 4620040. DOI: 10.1146/annurev-immunol-030409-101225. View

Regueiro M, Schraut W, Baidoo L, Kip K, Sepulveda A, Pesci M . Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2008; 136(2):441-50.e1. DOI: 10.1053/j.gastro.2008.10.051. View

10.

Gorelik L, Flavell R . Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000; 12(2):171-81. DOI: 10.1016/s1074-7613(00)80170-3. View

11.

Monteleone G, Fantini M, Onali S, Zorzi F, Sancesario G, Bernardini S . Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther. 2012; 20(4):870-6. PMC: 3321586. DOI: 10.1038/mt.2011.290. View

12.

Gorelik L, Flavell R . Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002; 2(1):46-53. DOI: 10.1038/nri704. View

13.

Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M . Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One. 2013; 8(1):e54562. PMC: 3547873. DOI: 10.1371/journal.pone.0054562. View

14.

Monteleone G, Kumberova A, Croft N, McKenzie C, Steer H, MacDonald T . Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001; 108(4):601-9. PMC: 209401. DOI: 10.1172/JCI12821. View

15.

Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F . Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997; 112(4):1169-78. DOI: 10.1016/s0016-5085(97)70128-8. View

16.

Monteleone G, Neurath M, Ardizzone S, Di Sabatino A, Fantini M, Castiglione F . Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015; 372(12):1104-13. DOI: 10.1056/NEJMoa1407250. View

17.

Boirivant M, Pallone F, Di Giacinto C, Fina D, Monteleone I, Marinaro M . Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006; 131(6):1786-98. DOI: 10.1053/j.gastro.2006.09.016. View

18.

Peyrin-Biroulet L, Loftus Jr E, Colombel J, Sandborn W . The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2009; 105(2):289-97. DOI: 10.1038/ajg.2009.579. View

19.

Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R . Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8(4):244-50. DOI: 10.1097/00054725-200207000-00002. View

20.

Olaison G, Smedh K, Sjodahl R . Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992; 33(3):331-5. PMC: 1373822. DOI: 10.1136/gut.33.3.331. View